In terms of efficacy, it is 60% efficacious for 18 to 64 and approximately 40% efficacious for the older population. However, when you look at effectiveness, it seems to have a 70% to 80% effectiveness in preventing hospitalizations and death, which is comparable to the other vaccines.
These are real-world data, which are not of the same high-standard quality as what we usually see in randomized control trials, but they are the data that we will have moving forward with the rollout of the vaccines. That's what we are also looking at.
In terms of preventing complications, it's good.